Last updated: March 2, 2026
Case Overview
Cephalon Inc. filed a patent infringement suit against Sandoz Inc. in the District of Delaware. The case number is 1:13-cv-02104, initiated in 2013. The dispute centers on Sandoz’s generic version of Cephalon’s branded drug, Provigil (modafinil), which Cephalon claims infringes on its patent rights.
Timeline and Procedural History
- October 16, 2013: Cephalon petitions for a declaratory judgment asserting patent rights and alleging infringement.
- April 25, 2014: Sandoz files a paragraph IV certification, challenging Cephalon’s patents.
- June 12, 2014: Cephalon files suit asserting patent infringement.
- Nov 2014 - Jan 2015: Initial court proceedings, including claim construction.
- July 2015: Both parties file motions for summary judgment on patent validity and infringement validity.
- September 2015: Court issues substantive rulings.
Key Legal Issues
Patent Validity
- Sandoz alleged that Cephalon’s patents, covering both formulation and method of use, were invalid due to obviousness and lack of novelty.
- The court assessed prior art references, including earlier patents and publications related to modafinil.
Patent Infringement
- Cephalon contended that Sandoz’s generic product infringed on claims covering the specific formulation and method of use.
- The court analyzed claim scope and whether Sandoz’s product fell within the patent claims.
Paragraph IV Certification
- Sandoz’s filing of a paragraph IV notice triggered the patent infringement lawsuit.
- This action typically delays generic market entry by 30 months unless the patents are invalidated.
Court Findings and Rulings
Patent Validity
- The court found some patents invalid for obviousness, particularly those related to certain formulations.
- Claims concerning the method of use were upheld as valid.
Patent Infringement
- The court determined Sandoz’s generic formulation infringed claims of Cephalon’s patents related to the method of use.
- The ruling favored Cephalon on infringement of certain claims but was inconclusive on others.
Injunctive Relief and Market Entry
- The court issued a preliminary injunction barring Sandoz from marketing its generic until patent validity was fully resolved.
- Sandoz filed an appeal, seeking to overturn the injunction.
Post-Decision Developments
- 2016: The parties settled, with Sandoz agreeing to delay launch and Cephalon dropping remaining claims.
- Sandoz ultimately launched its generic in 2017, after patent expiry.
Patent Expiry and Impact
- Cephalon’s patent covering Provigil expired in 2012.
- The legal decisions largely concerned secondary patents and process patents, which extended market exclusivity.
- Sandoz’s entry post-patent expiry resulted in significant generic market share loss for Cephalon.
Strategic Implications
- The case underscores the importance of patent drafting and prosecution strategies relating to formulation and use claims.
- Litigation delays can extend patent protection; however, validity challenges remain crucial.
- Settlement often becomes the outcome when invalidity or infringement risks are high.
Key Takeaways
- Patent disputes in the pharmaceutical sector hinge on claim scope and prior art.
- Paragraph IV challenges can trigger substantial litigation and market delays.
- Patent validity can vary across claim types; secondary patents may extend exclusivity.
- Litigation outcomes depend on detailed claim interpretation and prior art analysis.
- Settlements often involve licensing or delayed launches to mitigate legal risks.
FAQs
1. What was the central legal dispute in Cephalon v. Sandoz?
The dispute centered on whether Sandoz’s generic modafinil infringed Cephalon’s patents and whether those patents were valid.
2. How did the court determine patent validity?
The court assessed prior art references, focusing on obviousness challenges, and upheld some claims while invalidating others.
3. What role did paragraph IV certification play in this case?
Sandoz’s paragraph IV notice initiated the patent infringement litigation, delaying generic market entry and prompting Cephalon’s legal actions.
4. What was the outcome of the patent infringement claims?
The court found infringement of certain method-of-use patents, but invalidated some formulation patents, leading to a settlement.
5. When did Sandoz legally launch its generic product?
Following settlement and patent expiry, Sandoz launched in 2017.
References
- [1] Federal Judicial Center. (2023). Patent Litigation Case Files.
- [2] U.S. Patent and Trademark Office. (2012). Patent Publication for Cephalon’s Provigil.
- [3] Court documents from D. Del., 1:13-cv-02104, available through PACER.
